These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 23774084)

  • 1. Selective estrogen receptor modulators for BPH: new factors on the ground.
    Garg M; Dalela D; Dalela D; Goel A; Kumar M; Gupta G; Sankhwar SN
    Prostate Cancer Prostatic Dis; 2013 Sep; 16(3):226-32. PubMed ID: 23774084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective estrogen receptor modulators regulate stromal proliferation in human benign prostatic hyperplasia by multiple beneficial mechanisms--action of two new agents.
    Kumar R; Verma V; Sarswat A; Maikhuri JP; Jain A; Jain RK; Sharma VL; Dalela D; Gupta G
    Invest New Drugs; 2012 Apr; 30(2):582-93. PubMed ID: 21181231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Essential role for estrogen receptor beta in stromal-epithelial regulation of prostatic hyperplasia.
    McPherson SJ; Ellem SJ; Simpson ER; Patchev V; Fritzemeier KH; Risbridger GP
    Endocrinology; 2007 Feb; 148(2):566-74. PubMed ID: 17068134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia.
    Norman BH; Dodge JA; Richardson TI; Borromeo PS; Lugar CW; Jones SA; Chen K; Wang Y; Durst GL; Barr RJ; Montrose-Rafizadeh C; Osborne HE; Amos RM; Guo S; Boodhoo A; Krishnan V
    J Med Chem; 2006 Oct; 49(21):6155-7. PubMed ID: 17034120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective estrogen receptor-beta (SERM-beta) compounds modulate raphe nuclei tryptophan hydroxylase-1 (TPH-1) mRNA expression and cause antidepressant-like effects in the forced swim test.
    Clark JA; Alves S; Gundlah C; Rocha B; Birzin ET; Cai SJ; Flick R; Hayes E; Ho K; Warrier S; Pai L; Yudkovitz J; Fleischer R; Colwell L; Li S; Wilkinson H; Schaeffer J; Wilkening R; Mattingly E; Hammond M; Rohrer SP
    Neuropharmacology; 2012 Nov; 63(6):1051-63. PubMed ID: 22796107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgens and estrogens in benign prostatic hyperplasia: past, present and future.
    Nicholson TM; Ricke WA
    Differentiation; 2011; 82(4-5):184-99. PubMed ID: 21620560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of Eralpha and ERbeta in the prostate: insights from genetic models and isoform-selective ligands.
    McPherson SJ; Ellem SJ; Patchev V; Fritzemeier KH; Risbridger GP
    Ernst Schering Found Symp Proc; 2006; (1):131-47. PubMed ID: 17824175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogens and Male Lower Urinary Tract Dysfunction.
    Wynder JL; Nicholson TM; DeFranco DB; Ricke WA
    Curr Urol Rep; 2015 Sep; 16(9):61. PubMed ID: 26156791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current pharmacological treatment options for male lower urinary tract symptoms.
    Strittmatter F; Gratzke C; Stief CG; Hedlund P
    Expert Opin Pharmacother; 2013 Jun; 14(8):1043-54. PubMed ID: 23641819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen and androgen signaling in the pathogenesis of BPH.
    Ho CK; Habib FK
    Nat Rev Urol; 2011 Jan; 8(1):29-41. PubMed ID: 21228820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance.
    Lewis JS; Jordan VC
    Mutat Res; 2005 Dec; 591(1-2):247-63. PubMed ID: 16083919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanisms of selective estrogen receptor modulator (SERM) action.
    Dutertre M; Smith CL
    J Pharmacol Exp Ther; 2000 Nov; 295(2):431-7. PubMed ID: 11046073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogens and SERMs in coronary heart disease.
    Regitz-Zagrosek V; Wintermantel TM; Schubert C
    Curr Opin Pharmacol; 2007 Apr; 7(2):130-9. PubMed ID: 17317318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgens and estrogens: their interaction with stroma and epithelium of human benign prostatic hyperplasia and normal prostate.
    Krieg M; Bartsch W; Thomsen M; Voigt KD
    J Steroid Biochem; 1983 Jul; 19(1A):155-61. PubMed ID: 6193338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptor α and β.
    Rossi V; Bellastella G; De Rosa C; Abbondanza C; Visconti D; Maione L; Chieffi P; Della Ragione F; Prezioso D; De Bellis A; Bellastella A; Sinisi AA
    J Cell Physiol; 2011 May; 226(5):1334-9. PubMed ID: 20945400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of combination medical therapy in benign prostatic hyperplasia.
    Greco KA; McVary KT
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The selective estrogen receptor modulator trioxifene (LY133314) inhibits metastasis and extends survival in the PAIII rat prostatic carcinoma model.
    Neubauer BL; McNulty AM; Chedid M; Chen K; Goode RL; Johnson MA; Jones CD; Krishnan V; Lynch R; Osborne HE; Graff JR
    Cancer Res; 2003 Sep; 63(18):6056-62. PubMed ID: 14522935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen receptor modulators and estrogen receptor beta immunolabelling in human umbilical vein endothelial cells.
    Toth B; Scholz C; Saadat G; Geller A; Schulze S; Mylonas I; Friese K; Jeschke U
    Acta Histochem; 2009; 111(6):508-19. PubMed ID: 19004482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality?
    Tahmatzopoulos A; Kyprianou N
    Prostate; 2004 Apr; 59(1):91-100. PubMed ID: 14991869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolving Novel Chemical Entities for Management of Benign Prostatic Hyperplasia.
    Gupta S; Gupta G; Sharma VL
    Mini Rev Med Chem; 2017; 17(7):593-602. PubMed ID: 27484626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.